Immutep Limited

Immutep Limited is pleased to present its Q1 FY25 Quarterly Activities Report, showcasing robust progress in clinical trials, key regulatory milestones, and a solid cash position. Highlights include: - Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding regulatory preparations for the trial design - Efti in combination with MSD’s KEYTRUDA® reports positive efficacy and favourable safety in first-line head and neck cancer in TACTI-003 Phase IIb trial - First participant successfully dosed in the first-in-human Phase I trial of IMP761, a novel LAG-3 agonist antibody designed to treat autoimmune diseases Read the Quarterly Report: https://bit.ly/4f32nwh #biotechnology #LAG3 #immunotherapy #oncology

Immutep Limited will present new data from Cohort B of the TACTI-003 Phase IIb trial in first line recurrent/metastatic #HeadandNeckSquamousCellCarcinoma patients with negative PD-L1 expression (CPS <1) at the ESMO - European Society for Medical Oncology I-O Congress 2024 in Geneva, Switzerland in December. Read here: https://bit.ly/48nRrXv #biotechnology #LAG3 #oncology #HNSCC

Thank you Maxim Group LLC for hosting Immutep Limited at your 2024 Healthcare Virtual Summit.

During our 2024 Healthcare Virtual Summit, Maxim Senior Analysts hosted a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management. Access replays here: https://lnkd.in/gSPAicYu Aclarion, Inc. (ACON) Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) Aethlon Medical, Inc. (AEMD) AIM ImmunoTech Inc. (AIM) Alterity Therapeutics Limited (ATHE) Alzamend Neuro, Inc. (ALZN) Applied DNA Sciences, Inc. (APDN) Aprea Therapeutics, Inc. (APRE) Artelo Biosciences, Inc. (ARTL) Assertio Holdings, Inc. (ASRT) atai Life Sciences (ATAI) Atossa Therapeutics, Inc. (ATOS)  Autonomix Medical, Inc. (AMIX) Avenue Therapeutics (ATXI) Aytu BioPharma, Inc. (AYTU) Azitra Inc, Inc. (AZTR) Belite Bio, Inc. (BLTE) bioAffinity Technologies, Inc. (BIAF) Bionomics Ltd (BNOX) BioRestorative Therapies, Inc. (BRTX) Brainstorm Cell Therapeutics Inc. (BCLI) Chemomab Therapeutics Ltd. (CMMB) Citius Pharmaceuticals, Inc. (CTXR) Clene Nanomedicine, Inc. (CLNN) CNS Pharmaceuticals, Inc. (CNSP) Context Therapeutics Inc. (CNTX) Daxor Corporation (DXR) Dermata Therapeutics, Inc. (DRMA) electroCore, Inc.  (ECOR) Enlivex Therapeutics (Nasdaq: ENLV)   Femasys Inc. (FEMY) FibroBiologics (Nasdaq: FBLG) Gain Therapeutics, Inc. (GANX) Genelux Corporation (GNLX) Genenta Science S.p.A. (GNTA) Immuron Limited (IMRN) Immutep Limited (IMMP) Indaptus Therapeutics, Inc. (INDP) Inhibikase Therapeutics, Inc. (IKT) INmune Bio Inc. (INMB)

Immutep Limited is pleased to share its Annual Report for 2024. Dr Russell Howard said, "Our confidence in efti and its potential to make meaningful positive change in the treatment landscape for cancer patients is as strong as ever." Read here: https://bit.ly/4fbryfV #biotechnology #oncology #LAG3

Stocks of the Hour: Immutep, Altech Batteries, Cygnus Metals A snapshot of the stocks on the move, featuring Immutep Limited (ASX:IMM), Altech Batteries Limited (ASX:ATC) and Cygnus Metals (ASX:CY5). https://lnkd.in/g4BTTBxW

Immutep Limited announces the first part of the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761 has been fully recruited and the drug has been administered with no safety issues. Read: https://bit.ly/4hbfg8S #LAG3 #AutoimmuneDisease

Thank you, ausbiz and Nadine Blayney, for hosting CEO Marc Voigt to talk about Immutep’s progress in its #MetastaticBreastCancer trial, called AIPAC-003, which has just completed patient enrollment. Marc highlights Immutep Limited commitment to advancing #oncology research and setting new standards in global cancer care. Watch: https://bit.ly/3BBCu85 #biotechnology #ausbiz #BreastCancer

Immutep today announces completion of patient enrolment in the randomised Phase II portion of the AIPAC-003 trial in #MetastaticBreastCancer patients who’ve exhausted endocrine therapy. Read more here: https://bit.ly/3Y9I2ze

Thank you Finance News Network for hosting Marc Voigt to share his insights on Immutep Limited’s positive results in #headandneckcancer and an update on the TACTI-004 trial for #lungcancer.   Listen here: https://bit.ly/3N0RYoB #biotech #oncology #immunotherapy